时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, plasma p‐tau231 is less sensitive to longitudinal increases in amyloid pathology, brain atrophy, and cognitive impairment compared to other plasma p‐tau markers [].；However, characterization of cognitive diagnosis requires careful consideration of cognitive symptoms compared to a previous baseline, most often by a comprehensive neuropsychological assessment, and can be challenging.
方法
The Vanderbilt Memory and Aging Project (VMAP) is a longitudinal, observational cohort study [, ].；At enrollment between 2012 and 2014, Legacy Cohort participants were 60 years of age or older, free of clinical dementia, primary English speakers, possessed adequate auditory and visual acuity, and had a reliable study partner.；These participants were classified as cognitively unimpaired (CU), early MCI (eMCI) [], or MCI [].；Participants were excluded from enrolling into the Legacy Cohort for magnetic resonance imaging (MRI) contraindication, history of neurological disease (e.g., stroke, dementia), heart failure, major psychiatric illness, head injury with loss of consciousness > 5 min, and systemic or terminal illness that could impact follow‐up participation.
核心结论
Compared with participants included in the present study, excluded participants did not differ significantly in age (p = 0.51), education (p = 0.12), clinical diagnosis (p = 0.46), or APOE4 status (p = 0.73), although differences were observed in sex (p = 0.007) and race/ethnicity (p = 0.002).；Compared with amyloid‐ participants, amyloid+ participants included a smaller proportion of males (p = 0.006), had lower MoCA scores (p = 0.01), were more likely to have CC (p = 0.005), were more likely to be apolipoprotein E (APOE)‐ε4 carriers (p < 0.001) and to have MCI (p = 0.002).；Plasma p‐tau231 was significantly associated with amyloid positivity in the overall sample (OR = 1.180, p < 0.001; AUC = 0.73; PPV = 63%; NPV = 64%; see Table ). ‖ 结论：These findings emphasize that BBMs may not have uniform performance across individuals and that considering both subjective and objective cognitive measures may improve their interpretation.
局限
Several limitations should be acknowledged.；Although this cohort is deeply characterized, the sample was predominantly White and highly educated, which may limit generalizability to more diverse populations.；Furthermore, participants tend to be relatively healthy, As a result, the findings may not be generalizable to people in the broader community who have medical conditions known to affect blood biomarker levels, such as chronic kidney disease [].
对本项目的价值
★☆☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 23,583 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening.
- 期刊与标识：Ann Clin Transl Neurol · PMID 42957617 · DOI 10.1002/acn3.70565
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。